Vaxcyte, Inc. PCVX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Vaxcyte, Inc. (PCVX) reported accretion (amortization) of discounts and premiums, investments of $3.11M in Q1 2026.
- How has Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 36.7% year-over-year, from $4.91M to $3.11M.
- What is the long-term trend for Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 79.0% compound annual growth rate (CAGR), from -$1.41M to $14.43M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of investment securities resulting from the amortization of premiums or accretion of discounts. It reflects the systematic recognition of interest income over the life of the investment, adjusting the reported net income to reflect the effective yield. This metric is essential for understanding the true economic interest earned on a company's investment portfolio.